AMOXAPINE VERSUS AMITRIPTYLINE IN ENDOGENOUS-DEPRESSION - DOUBLE-BLIND-STUDY

A new antidepressant, amoxapine, which is a dibenzoxazepine derivative, was compared with amitriptyline in a randomised double‐blind trial. Forty‐eight patients were included and 41 completed a 4‐week treatment. Most of the patients were maintained on 150 mg daily. Assessments were made by the Hamilton Psychiatric Rating Scale for Depression (HAM‐D), Nurses' Observation Scale for In‐patient Evaluation (NOSIE), Clinical Global Impression (CGI) scale and Patient's Self‐Evaluation. The total HAM‐D score was considerably reduced in the majority of the patients. Amitriptyline was the most effective with regard to symptoms included in the factor Sleep Disturbances and ‐ secondary maybe ‐ towards some items included in the factor Somatization. For the remaining items, including the items of the factors Anxiety/Depression and Apathy, the last score was lower in the amoxapine group than in those treated with amitriptyline. Among the unipolar cases the amoxapine treated patients were more satisfied with regard to efficacy (P= 6.3 %). The frequency of side effects such as tremor and dizziness was considerably lower in the amoxapine group. In total, the side effects lasted longer in the amitriptyline group. We conclude that amoxapine seems to be an effective antidepressant with a low frequency of side effects. Copyright © 1979, Wiley Blackwell. All rights reserved